



FOR IMMEDIATE RELEASE

CONTACT:
Kelly Sladek
SCORR Marketing
308.237.5567
Kelly@scormarketing.com

KCAS Announces ACOG Poster Presentation and Attendance at Upcoming Tradeshows

(Shawnee, Kansas; May 11, 2010) – [KCAS, LLC](#), a bioanalytical laboratory specializing in high-quality research and analytical services for pharmaceutical, biotech, animal health and medical device companies, announces its poster presentation discussing the use of alkaline hematin as a quantitative endpoint for menstrual blood loss (MBL) in clinical trials, as well as KCAS' attendance at two upcoming tradeshows.

KCAS will be attending the [American Congress of Obstetricians and Gynecologists](#) (ACOG) Annual Clinical Meeting, May 15-19, 2010, in San Francisco, California, at the Moscone Convention Center. Gene F. Ray, Ph.D., will be presenting his poster titled "Rapid Quantitation of Menstrual Blood Loss from Feminine Hygiene Products" on Monday, May 17, from 10:30 am to 4:30 pm in room 103.

Dr. Ray's presentation will discuss KCAS' proprietary, validated method for quantitative measurement of MBL as [alkaline hematin](#). On April 7, KCAS presented this method to the FDA as an alternative to pictograms, which have been commonly used in the past. Over the course of three years, KCAS has run approximately 90,000 samples supporting both drug and device studies that use the alkaline hematin assay as a definitive MBL endpoint for investigational treatments for menorrhagia. One of these products has been approved by the FDA.

"Dr. Ray has devoted countless hours of research to this topic," said President and Scientific Director of KCAS, Dari Dadgar, Ph.D. "Alkaline hematin presents a very niche market and one we believe is of high importance and value to women's health programs."

KCAS will also be in attendance, at Booth 119, at the [American Association of Pharmaceutical Scientists National Biotechnology Conference](#) (AAPS NBC), May 16-19, 2010, in San Francisco, California.

Learn the latest on how to apply alkaline hematin as a MBL endpoint marker for your women's health trials with KCAS' webinar on Wednesday, July 14, 2010, from 11:30 am to 1:00 pm CDT. To register for this webinar, click [here](#).

About KCAS, LLC

KCAS provides a full range of high-quality analytical services, specializing in bioanalytical research by "*Advancing Science Through Curiosity™*," to pharmaceutical companies of all sizes. For more than 30 years, KCAS has completed over 800 bioanalytical assays and thousands of PK, TK and BE studies. KCAS produces reliable and high-quality results for small molecule, large molecule and biomarker analysis. For more information about KCAS, visit www.kcasbio.com.

###